Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised KKR in connection with the acquisition of Gunnebo Industrier
Mandate

Vinge has advised KKR in connection with the acquisition of Gunnebo Industrier

May 22, 2019 M&A

Vinge has advised the global investment company, KKR in connection with the acquisition by its portfolio company Crosby of Gunnebo Industrier from Segulah and minority investors.

Crosby is a global, market‑leading company with products within lifting and rigging. Gunnebo Industrier is an international manufacturing group that provides lifting and material handling products to a global customer base. The company was founded in 1764 and has manufacturing units in Sweden, Norway and the USA with subsidiaries in nine countries and distribution partners in more than 50 countries.

Vinge’s team consisted of, among others, Christina Kokko, Samra Baytar, Marith Welin-Berger and Hanna Risberg (Corporate and M&A), Adriana Berglund and Michael Montner (Commercial Agreements), Lisa Ullman (Employment), André Isacson and Josefine Larsson (Banking and Finance), Klara Secher and Hannah Kajlinger (IP), Kristoffer Larson (Real Property), Agnes Perbo and Nicklas Thorgerzon (IT) and Jessica Öijer (VDR assistant).

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024